The treatment of BT-474 breast cancer cell-derived tumours in a xenograft model with a combination of SGK and Akt inhibitors induced greater tumour regression than achieved through the administration of either inhibitor alone [17]. The gene discussed is AKT1; the disease is breast carcinoma.